WCM Investment Management LLC Has $12.39 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

WCM Investment Management LLC increased its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 1,153.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 187,807 shares of the medical research company's stock after purchasing an additional 172,821 shares during the quarter. WCM Investment Management LLC owned 0.10% of Exact Sciences worth $12,388,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Chicago Partners Investment Group LLC increased its holdings in Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company's stock valued at $651,000 after buying an additional 158 shares during the last quarter. Amalgamated Bank increased its holdings in Exact Sciences by 2.7% in the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company's stock worth $462,000 after buying an additional 284 shares during the last quarter. Midwest Professional Planners LTD. lifted its stake in shares of Exact Sciences by 12.3% in the first quarter. Midwest Professional Planners LTD. now owns 3,088 shares of the medical research company's stock worth $213,000 after buying an additional 339 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company's stock worth $49,000 after purchasing an additional 340 shares during the last quarter. Finally, CIBC Asset Management Inc grew its holdings in Exact Sciences by 6.2% in the 2nd quarter. CIBC Asset Management Inc now owns 6,118 shares of the medical research company's stock valued at $258,000 after buying an additional 356 shares during the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EXAS has been the subject of several research reports. Craig Hallum reduced their price objective on Exact Sciences from $82.00 to $65.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company started coverage on Exact Sciences in a report on Tuesday, August 27th. They set an "overweight" rating and a $75.00 price objective on the stock. Robert W. Baird reduced their target price on Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Benchmark lowered their price target on shares of Exact Sciences from $67.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group decreased their target price on shares of Exact Sciences from $95.00 to $75.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Exact Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $74.47.

Insider Transactions at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.36% of the company's stock.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS traded down $1.17 during trading on Tuesday, reaching $50.16. 4,164,118 shares of the company's stock traded hands, compared to its average volume of 2,625,989. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a 50-day simple moving average of $66.55 and a 200-day simple moving average of $56.41. The company has a quick ratio of 1.98, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The firm has a market cap of $9.28 billion, a PE ratio of -43.87 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million during the quarter, compared to analysts' expectations of $716.80 million. The company's quarterly revenue was up 12.8% compared to the same quarter last year. As a group, analysts predict that Exact Sciences Co. will post -1.02 earnings per share for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.